Evidence map›Paper›PMID 37005668›Full record

ArticleJournal of nanobiotechnology2023

Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.

Hao Zhang, Wang Zhang, Bochuan Hu, Xiaohua Qin, Tianxiang Yi, Yayi Ye, Xiaowan Huang, Yang Song, Zhenyu Yang, Jieying Qian and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Mutant p53 regulates reversible subtype plasticity in pancreatic cancer.Cellular and molecular life sciences : CMLS · 2025
    Article
  3. Biochemistry and biophysics reports · 2025
    Article
  4. Review
  5. Mitochondrial Reactive Oxygen Species (mROS) Generation and Cancer:International journal of nanomedicine · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hao ZhangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Wang ZhangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Bochuan HuSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Xiaohua QinSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Tianxiang YiSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Yayi YeSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Xiaowan HuangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Yang SongSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Zhenyu YangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Jieying QianSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China. qianjieying1314@scut.edu.cn.
Yunjiao ZhangSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China. zhangyunjiao@scut.edu.cn.
South China University of Technology · CN

Funding

Basic and Applied Basic Research of Guangzhou 2023A04J1821Key R&D Program of Guangdong Province 2020B1515120096National Natural Science Foundation of China 82202305National Natural Science Foundation of China T2222014Program for Guangdong Introducing Innovative and Entrepreneurial Teams 2017ZT07S054
6 · The paper itself

Abstract

backgroundIn a significant proportion of cancers, point mutations of TP53 gene occur within the DNA-binding domain, resulting in an abundance of mutant p53 proteins (mutp53) within cells, which possess tumor-promoting properties. A potential and straightforward strategy for addressing p53-mutated cancer involves the induction of autophagy or proteasomal degradation. Based on the previously reported findings, elevating oxidative state in the mutp53 cells represented a feasible approach for targeting mutp53. However, the nanoparticles previous reported lacked sufficient specificity of regulating ROS in tumor cells, consequently resulted in unfavorable toxicity in healthy cells.

resultsWe here in showed that cerium oxide CeO

conclusionsOverall, CeO

Indexed as

CeriumNanoparticlesPancreatic NeoplasmsCell Line, TumorGenes, p53HumansMutant ProteinsReactive Oxygen SpeciesTumor Suppressor Protein p53ceric oxideCeriumMutant ProteinsReactive Oxygen SpeciesTumor Suppressor Protein p53Cancer therapyCeO2 nanoparticles (CeO2 NPs)mutp53 degradationUbiquitination proteasome

Identifiers

PMID37005668
PMCPMC10067194
OpenAlexW4362521776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.